DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • South Korea
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
A006620 logo

DongKoo Bio & Pharma Co., Ltd. Stock Price

KOSDAQ:A006620 Community·₩94.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

A006620 Share Price Performance

₩3,500.00
-1550.00 (-30.69%)
​
₩3,500.00
-1550.00 (-30.69%)
​
Price ₩3,500.00
Sat, 12 Sep 26
Share Pricen/a

A006620 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Solid track record with low risk.

3 Risks
2 Rewards
View Full Analysis

DongKoo Bio & Pharma Co., Ltd. Key Details

₩241.4b

Revenue

₩101.7b

Cost of Revenue

₩139.7b

Gross Profit

₩106.7b

Other Expenses

₩33.0b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.22k
57.87%
13.67%
85.1%
View Full Analysis

About A006620

Founded
1970
Employees
404
CEO
Cho Yong-Jun
WebsiteView website
www.dongkoo.com

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs. It offers cosmetic products under the CELL BLOOM brand; MediBloom MD Lotion/Cream for wound treatment; and medical devices for skin therapy, aesthetic, scalp care, and skin diagnosis. In addition, the company develops DKB15003 for dyslipidemia; DKB17001 for BPH/OAB; DKB17002 for Lumbago; DKB19001 for hypertension/dyslipidemia; DKB19002, DKB20001, DKB20002, DKB20004, DKB1903, DKB1903C, and DKB2001 for diabetes; DKB19003 for allergic rhinitis; DKB20003 for venous lymphatic insufficiency; NCP112 for atopic dermatitis; DKB1904 for allergy/dermatitis; DKB1801 for acne; and DKB1902 and DKB2014 for psoriasis. Further, it engages in new technology, financial, pharmaceutical marketing, and agency businesses. The company was formerly known as DongKoo Pharm Co., Ltd. and changed its name to DongKoo Bio & Pharma Co., Ltd. in January 2014. The company was founded in 1970 and is headquartered in Seoul, South Korea.

Recent A006620 News & Updates

Analysis Article • Apr 01

DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings Are Built On Soft Foundations

Solid profit numbers didn't seem to be enough to please DongKoo Bio & Pharma Co., Ltd.'s ( KOSDAQ:006620...

Recent updates

No updates

DongKoo Bio & Pharma Co., Ltd. Competitors

A207940 logo

Samsung BiologicsLtd

Symbol: KOSE:A207940
Market cap: ₩65.4t
A068270 logo

Celltrion

Symbol: KOSE:A068270
Market cap: ₩42.8t
A196170 logo

ALTEOGEN

Symbol: KOSDAQ:A196170
Market cap: ₩18.7t
A0126Z0 logo

Samsung Epis Holdings

Symbol: KOSE:A0126Z0
Market cap: ₩8.4t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide